Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moritz J Rossner

Showing results (91-100 of 95) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 95 results.
Science Advances|September 16, 2022
Ketogenic diet uncovers differential metabolic plasticity of brain cellsTim Düking, Lena Spieth, Stefan A Berghoff, et al.
Communications Medicine|June 16, 2026
Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning clinical trialAlkomiet Hasan, Stefan Leucht, Astrid Roeh, et al.
JAMA Psychiatry|March 28, 2026
Bridging the Scales via Personalized Cellular Modeling and Deep Phenotyping in SchizophreniaFlorian J Raabe, David Popovic, Clara Vetter, et al.
Journal of Affective Disorders|January 31, 2026
Personal recovery as outcome measure in mental health research: A meta-analysis on the sensitivity to change properties of the Recovery Assessment ScaleT A D Pelgrim, K Kleine Schaars, R Moldovan, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2024
Polygenic risk for schizophrenia converges on alternative polyadenylation as molecular mechanism underlying synaptic impairmentFlorian J Raabe, Anna Hausruckinger, Miriam Gagliardi, et al.
Pageof 10

Showing results (91-100 of 95) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 95 results.
Science Advances|September 16, 2022
Ketogenic diet uncovers differential metabolic plasticity of brain cellsTim Düking, Lena Spieth, Stefan A Berghoff, et al.
Communications Medicine|June 16, 2026
Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning clinical trialAlkomiet Hasan, Stefan Leucht, Astrid Roeh, et al.
JAMA Psychiatry|March 28, 2026
Bridging the Scales via Personalized Cellular Modeling and Deep Phenotyping in SchizophreniaFlorian J Raabe, David Popovic, Clara Vetter, et al.
Journal of Affective Disorders|January 31, 2026
Personal recovery as outcome measure in mental health research: A meta-analysis on the sensitivity to change properties of the Recovery Assessment ScaleT A D Pelgrim, K Kleine Schaars, R Moldovan, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2024
Polygenic risk for schizophrenia converges on alternative polyadenylation as molecular mechanism underlying synaptic impairmentFlorian J Raabe, Anna Hausruckinger, Miriam Gagliardi, et al.
Pageof 10